Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years

  • Dermavant Sciences, a Roivant Sciences Ltd. ROIV company, announced results from ADORING 2 Phase 3 study evaluating VTAMA (tapinarof) cream, 1% in pediatric subjects down to 2 years old and adult subjects with atopic dermatitis (AD).
  • In ADORING 2 (N=406), VTAMA cream met the primary endpoint of the trial and demonstrated highly statistically significant improvement in the vIGA-AD score of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8.
  • Additionally, VTAMA cream demonstrated a statistically significant improvement in the proportion of subjects with >75% improvement in EASI75 from baseline at week 8, a key secondary endpoint.
  • Subjects 12 years and older receiving VTAMA cream also experienced a highly statistically significant improvement >4-point reduction in Peak Pruritis Numeric Rating Scale (PP-NRS) in itch.
  • VTAMA cream data indicated no safety or tolerability signals. 
  • In May 2022, the FDA approved VTAMA (tapinarof) cream, 1% for adult plaque psoriasis.
  • Price Action: ROIV shares are up 10.3% at $8.78 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!